# Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC

> **NCT07041788** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Second Affiliated Hospital of Nanchang University** · enrollment: 25 (estimated)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Iparomlimab and Tuvonralimab Injection

## Key facts

- **NCT ID:** NCT07041788
- **Lead sponsor:** Second Affiliated Hospital of Nanchang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-28
- **Primary completion:** 2028-07-09
- **Final completion:** 2030-07-09
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07041788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07041788, "Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT07041788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*